Cover Image
市場調查報告書

膀胱過動症:開發平台分析

Overactive Bladder - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 192758
出版日期 內容資訊 英文 124 Pages
訂單完成後即時交付
價格
Back to Top
膀胱過動症:開發平台分析 Overactive Bladder - Pipeline Review, H2 2016
出版日期: 2016年10月12日 內容資訊: 英文 124 Pages
簡介

所謂膀胱過動症是膀胱的儲存機能發生問題,讓人突然感到尿意的疾病。這種情況下非常難抑制尿意,結果甚至可能造成不自主排尿(尿失禁)。其他症狀有一晚感到2∼3回尿意起床。主要治療方法有改善生活習慣、透過藥物治療緩和膀胱活動,防止失禁等。

本報告提供全球各國治療膀胱過動症所用之開發中產品的開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

膀胱過動症概要

治療藥的開發

  • 膀胱過動症開發中產品:概要
  • 膀胱過動症開發中產品:比較分析

各企業開發中的膀胱過動症治療藥

大學/研究機關研究中的膀胱過動症治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

膀胱過動症治療藥:開發中的產品一覽(各企業)

膀胱過動症治療藥:研究中的產品一覽(大學/研究機關別)

膀胱過動症開發治療藥的企業

  • Addex Therapeutics Ltd
  • Allergan Plc
  • AltheRx Pharmaceuticals, Inc.
  • 旭化成製藥
  • Astellas Pharma Inc.
  • Dong-A Socio Group
  • FemmePharma Global Healthcare, Inc.
  • Ferring International Center S.A.
  • Hydra Biosciences, Inc.
  • Ion Channel Innovations, LLC
  • Ipsen S.A.
  • Jeil Pharmaceutical Co., Ltd.
  • Laboratorios SALVAT S.A.
  • Lipella Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Mezzion Pharma Co. Ltd.
  • MI.TO. Technology S.r.L.
  • NeuroSearch A/S
  • Recordati S.p.A.
  • Sanofi
  • 武田藥品工業
  • TARIS BioMedical, Inc.
  • TheraVida, Inc.
  • Toray Industries

膀胱過動症:治療藥的評估

  • 單劑治療藥的情況
  • 並用治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • mirabegron
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • solifenacin succinate
  • (mirabegron + solifenacin succinate)
  • diltiazem hydrochloride
  • dexmecamylamine
  • SCH-900978
  • oxybutynin
  • abobotulinumtoxinA
  • solabegron hydrochloride
  • MK-4618
  • senrebotase
  • (tolterodine + pilocarpine)
  • tarafenacin
  • oxybutynin
  • onabotulinumtoxinA liposomal
  • REC-1819
  • URG-302
  • pVAX-hSlo
  • THVD-202
  • REC-0438
  • TRK-380
  • KEA-0477
  • udenafil
  • ADX-71441
  • HC-067047
  • REC-0436
  • fesoterodine
  • solifenacin
  • darifenacin
  • Small Molecule GABABR PAM Program
  • tacrolimus liposomal
  • AE-9C90CB
  • SAR-244181
  • MTF-002
  • Small Molecule to Inhibit TRPV1 for Overactive Bladder
  • TD-302
  • PACAP6-38
  • Small Molecules to Agonize Beta3-Adrenoceptor for Anxiety, Depression and Overactive Bladder
  • Small Molecule To Antagonize Neurokinin-1 Receptor For Overactive Bladder
  • (tolterodine + pilocarpine)
  • THVD-202

膀胱過動症治療藥:開發中產品的最新趨勢

膀胱過動症治療藥:開發暫停的產品

膀胱過動症治療藥:開發中止的產品

膀胱過動症相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8530IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Overactive Bladder - Pipeline Review, H2 2016, provides an overview of the Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline landscape.

Overactive bladder is a problem with bladder-storage function that causes a sudden urge to urinate. The urge may be difficult to stop, and overactive bladder may lead to the involuntary loss of urine (incontinence). Symptoms include feel a sudden urge to urinate that's difficult to control, experience urge incontinence and awaken two or more times in the night to urinate. Treatment includes change in life style and medications that relax the bladder can be effective for relieving symptoms of overactive bladder and reducing episodes of urge incontinence.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Overactive Bladder - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Overactive Bladder (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Overactive Bladder and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 7, 4, 4, 2, 10 and 1 respectively for Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively for Overactive Bladder.

Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Overactive Bladder (Genito Urinary System And Sex Hormones).
  • The pipeline guide reviews pipeline therapeutics for Overactive Bladder (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Overactive Bladder (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Overactive Bladder (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Overactive Bladder (Genito Urinary System And Sex Hormones)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Overactive Bladder (Genito Urinary System And Sex Hormones).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Overactive Bladder Overview
  • Therapeutics Development
    • Pipeline Products for Overactive Bladder - Overview
    • Pipeline Products for Overactive Bladder - Comparative Analysis
  • Overactive Bladder - Therapeutics under Development by Companies
  • Overactive Bladder - Therapeutics under Investigation by Universities/Institutes
  • Overactive Bladder - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Overactive Bladder - Products under Development by Companies
  • Overactive Bladder - Products under Investigation by Universities/Institutes
  • Overactive Bladder - Companies Involved in Therapeutics Development
    • Addex Therapeutics Ltd
    • Allergan Plc
    • Asahi Kasei Pharma Corp.
    • Astellas Pharma Inc.
    • Dompe Farmaceutici S.p.A.
    • Dong-A Socio Holdings Co. Ltd.
    • FemmePharma Global Healthcare, Inc.
    • Hanmi Pharmaceuticals, Co. Ltd.
    • Hydra Biosciences, Inc.
    • Ion Channel Innovations, LLC
    • Ipsen S.A.
    • Jeil Pharmaceutical Co., Ltd.
    • Juniper Pharmaceuticals, Inc.
    • Lipella Pharmaceuticals, Inc.
    • Merck & Co., Inc.
    • Mezzion Pharma Co. Ltd.
    • Ono Pharmaceutical Co., Ltd.
    • Recordati S.p.A.
    • Sanofi
    • Seoul Pharma Co., Ltd.
    • Taris Biomedical LLC
    • TheraVida, Inc.
    • Toray Industries, Inc.
    • UroGen Pharmaceuticals, Ltd.
    • XuanZhu Pharma Co., Ltd.
  • Overactive Bladder - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (mirabegron + solifenacin succinate) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (solifenacin succinate + tamsulosin hydrochloride) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • abobotulinumtoxin A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ADX-71441 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DA-8010 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DFL-23448 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fadanafil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HC-067047 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HIP-1503 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mirabegron ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • onabotulinumtoxin A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • onabotulinumtoxinA - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • onabotulinumtoxinA SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ONO-8577 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • oxybutynin chloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • oxybutynin chloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptide to Antagonize PACAP Receptor for Pelvic Pain Syndrome and Overactive Bladder - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pVAX-hSlo - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • REC-0438 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SAR-244181 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Block TRPV1 for Overactive Bladder - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize EP1 Receptor for Overactive Bladder - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • solabegron hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • solifenacin succinate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SPO-1406 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tacrolimus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAR-302 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • THVD-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • udenafil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vibegron - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Overactive Bladder - Dormant Projects
  • Overactive Bladder - Discontinued Products
  • Overactive Bladder - Product Development Milestones
    • Featured News & Press Releases
      • Sep 27, 2016: Allergan to Present New Data at the American Urogynecologic Society Annual Meeting in Denver
      • May 03, 2016: Allergan Presents New Data on OnabotulinumtoxinA at the American Urological Association Meeting in San Diego
      • Mar 21, 2016: Juniper Pharmaceuticals Affirms Development Pathway for Oxybutynin Intra-vaginal Ring for Overactive Bladder in Women
      • Jan 11, 2016: Juniper Pharmaceuticals Submits Pre-IND Meeting Request for its First Intra-vaginal Ring Product
      • Oct 15, 2015: Allergan Announces New Long-Term OnabotulinumtoxinA Treatment Study Results at the American Urogynecologic Society Meeting
      • Jun 15, 2015: NeXeption Forms New Company Velicept Therapeutics Intends to Merge with AltheRx Pharmaceuticals to Advance Solabegron for the Treatment of Overactive Bladder
      • May 17, 2015: Mirabegron As Add-On Treatment To Solifenacin Therapy Demonstrated Superior Results To Solifenacin Monotherapy In BESIDE Trial
      • May 05, 2015: Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting
      • Dec 08, 2014: Lipella's Liposome Formulation of Botulinum Toxin (LP-09) Superior to Placebo for Overactive Bladder Symptoms in Double-Blind Trial
      • Apr 08, 2014: Positive Clinical Trial Results of Topical Botulinum Toxin for Overactive Bladder
      • Oct 17, 2013: AltheRx Pharmaceuticals is Granted U.S. Patent for Use of Solabegron in Combination with Antimuscarinics for the Treatment of Overactive Bladder
      • Sep 11, 2013: Allergan's BOTOX Receives Authorisation for the Treatment of Overactive Bladder in the UK
      • Jul 03, 2013: Impax Laboratories Confirms Patent Challenge Relating to Generic TOVIAZ 4 mg and 8 mg
      • May 21, 2013: Addex Validates Potential Efficacy Biomarker For Phase I Trial Of ADX71441
      • May 17, 2013: Astellas's Betmiga Obtains NICE Recommendation For Restricted Use In Treatment Of Overactive Bladder
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Overactive Bladder, H2 2016
  • Number of Products under Development for Overactive Bladder - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Overactive Bladder - Pipeline by Addex Therapeutics Ltd, H2 2016
  • Overactive Bladder - Pipeline by Allergan Plc, H2 2016
  • Overactive Bladder - Pipeline by Asahi Kasei Pharma Corp., H2 2016
  • Overactive Bladder - Pipeline by Astellas Pharma Inc., H2 2016
  • Overactive Bladder - Pipeline by Dompe Farmaceutici S.p.A., H2 2016
  • Overactive Bladder - Pipeline by Dong-A Socio Holdings Co. Ltd., H2 2016
  • Overactive Bladder - Pipeline by FemmePharma Global Healthcare, Inc., H2 2016
  • Overactive Bladder - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2016
  • Overactive Bladder - Pipeline by Hydra Biosciences, Inc., H2 2016
  • Overactive Bladder - Pipeline by Ion Channel Innovations, LLC, H2 2016
  • Overactive Bladder - Pipeline by Ipsen S.A., H2 2016
  • Overactive Bladder - Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2016
  • Overactive Bladder - Pipeline by Juniper Pharmaceuticals, Inc., H2 2016
  • Overactive Bladder - Pipeline by Lipella Pharmaceuticals, Inc., H2 2016
  • Overactive Bladder - Pipeline by Merck & Co., Inc., H2 2016
  • Overactive Bladder - Pipeline by Mezzion Pharma Co. Ltd., H2 2016
  • Overactive Bladder - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016
  • Overactive Bladder - Pipeline by Recordati S.p.A., H2 2016
  • Overactive Bladder - Pipeline by Sanofi, H2 2016
  • Overactive Bladder - Pipeline by Seoul Pharma Co., Ltd., H2 2016
  • Overactive Bladder - Pipeline by Taris Biomedical LLC, H2 2016
  • Overactive Bladder - Pipeline by TheraVida, Inc., H2 2016
  • Overactive Bladder - Pipeline by Toray Industries, Inc., H2 2016
  • Overactive Bladder - Pipeline by UroGen Pharmaceuticals, Ltd., H2 2016
  • Overactive Bladder - Pipeline by XuanZhu Pharma Co., Ltd., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Overactive Bladder - Dormant Projects, H2 2016
  • Overactive Bladder - Dormant Projects (Contd..1), H2 2016
  • Overactive Bladder - Dormant Projects (Contd..2), H2 2016
  • Overactive Bladder - Dormant Projects (Contd..3), H2 2016
  • Overactive Bladder - Dormant Projects (Contd..4), H2 2016
  • Overactive Bladder - Dormant Projects (Contd..5), H2 2016
  • Overactive Bladder - Discontinued Products, H2 2016
  • Overactive Bladder - Discontinued Products (Contd..1), H2 2016

List of Figures

  • Number of Products under Development for Overactive Bladder, H2 2016
  • Number of Products under Development for Overactive Bladder - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top